Register entry
- Registered sites
- 0
- Active NDC listings
- 19
- Labeller names
- 3
- Live patents
- 17
- Countries
- 0
Catalogue
Drug listings by form and route
1919 active NDC listings: 19 human prescription drug. By marketing category: NDA 14, ANDA 5.
| Dosage form | NDCs |
|---|---|
| tablet | 11 |
| tablet, orally disintegrating | 4 |
| tablet, delayed release | 2 |
| capsule | 1 |
| injection | 1 |
| Route | NDCs |
|---|---|
| oral | 18 |
| subcutaneous | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| cycle pharmaceuticals ltd | 10 |
| cycle pharmaceuticals ltd. | 8 |
| cycle pharmaceuticals ltd-uk | 1 |
Exclusivity
Patents and exclusivities
17| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10328029 | NITYRnitisinone | product | Jan 2035 |
| 10555902 | TASCENSO ODTfingolimod lauryl sulfate | use | Jan 2036 |
| 10925829 | TASCENSO ODTfingolimod lauryl sulfate | product | Jan 2036 |
| 9925138 | TASCENSO ODTfingolimod lauryl sulfate | product | Jan 2036 |
| 11389450 | CAVHANZAnilotinib | use | Jan 2041 |
| 12016861 | CAVHANZAnilotinib | use | Jan 2041 |
| 12029740 | CAVHANZAnilotinib | product | Jan 2041 |
| 11559485 | CAVHANZAnilotinib | product | Apr 2041 |
Catalogue
Marketed products
19| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| AAGYLUR | Penicillamine | capsule, oral | 70709-102ANDA |
| CAVHANZA | Nilotinib | tablet, orally disintegrating, oral | 70709-191NDA |
| CAVHANZA | Nilotinib | tablet, orally disintegrating, oral | 70709-192NDA |
| HARLIKU | nitisinone | tablet, oral | 70709-112NDA |
| NITYR | Nitisinone | tablet, oral | 70709-000NDA |
| NITYR | Nitisinone | tablet, oral | 70709-002NDA |
| NITYR | Nitisinone | tablet, oral | 70709-005NDA |
| ORMALVI | Dichlorphenamide | tablet, oral | 70709-085ANDA |
| PHYRAGO | dasatinib | tablet, oral | 70709-151NDA |
| PHYRAGO | dasatinib | tablet, oral | 70709-152NDA |
| PHYRAGO | dasatinib | tablet, oral | 70709-153NDA |
| PHYRAGO | dasatinib | tablet, oral | 70709-154NDA |
| PHYRAGO | dasatinib | tablet, oral | 70709-155NDA |
| PHYRAGO | dasatinib | tablet, oral | 70709-156NDA |
| SAJAZIR | ICATIBANT | injection, subcutaneous | 70709-013ANDA |
| TASCENSO ODT | Fingolimod Lauryl Sulfate | tablet, orally disintegrating, oral | 70709-062NDA |
| TASCENSO ODT | Fingolimod Lauryl Sulfate | tablet, orally disintegrating, oral | 70709-065NDA |
| VENXXIVA | tiopronin | tablet, delayed release, oral | 70709-121ANDA |
| VENXXIVA | tiopronin | tablet, delayed release, oral | 70709-123ANDA |
Compare
Other companies listing dasatinib
- Patheon Manufacturing Services LLC19 sites · 319 NDC
- Zydus Lifesciences Limited12 sites · 717 NDC
- Biocon Biologics Limited9 sites · 176 NDC
- SK BIOTEK2 sites · 10 NDC
- Zydus Pharmaceuticals USA Inc.1 site · 626 NDC
- BluePoint Laboratories Inc.0 sites · 352 NDC
- Prasco Laboratories0 sites · 106 NDC
- E.R. Squibb & Sons, L.L.C.0 sites · 51 NDC
Enquiry
Common questions
- Is Cycle Pharmaceuticals Ltd-Uk FDA approved?
- Cycle Pharmaceuticals Ltd-Uk holds no registered establishment of its own; 19 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Cycle Pharmaceuticals Ltd-Uk make?
- 19 products are listed under Cycle Pharmaceuticals Ltd-Uk in the openFDA NDC Directory, most often as tablet; tablet, orally disintegrating; tablet, delayed release. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.